Catamaran Corp., a pharmacy benefit management company, recently announced that it is launching a new clinical outcomes-based program for hepatitis C treatment.
The program, which will be conducted through Catamaran’s specialty pharmacy, BriovaRx, will provide clients with new hepatitis C treatments and focus on generating positive health results.
Participants will be monitored for the entirety of the program to ensure and support full consistency in the program. To increase adherence, the Hepatitis C Patient Management Program has a nurse team that creates individual care-plans for each patient.
“Catamaran and BriovaRx are rooted in delivering a more integrated health care experience for patients through a holistic and personalized approach,” Dr. Sumit Dutta, senior vice president and chief medical officer at Catamaran, said. “Our clinical outcomes-based program for hepatitis C supports this mission, empowering our nurses and pharmacists to partner with patients in a way that truly drives better health outcomes and ensures these high-cost therapies accomplish what they were designed to do."
Harvoni and Sovaldi, hepatitis C treatments from Gilead Science, Inc., are the sole options on Catamaran’s National and Value Formularies. Catamaran’s commercial clients can participate in the program if they use Harvoni or Sovaldi, or if they have a custom formulary and opt-in.